Piritrexim — CAS 3562-39-8

Piritrexim is a lipophilic antifolate that inhibits dihydrofolate reductase (DHFR) and was investigated for the treatment of Pneumocystis jirovecii pneumonia (PCP) and toxoplasmosis in immunocompromised patients. Mediocon Inc manufactures this API at its GMP-certified facility in Aurangabad, Maharashtra, India.

• Treatment and prophylaxis of Pneumocystis jirovecii pneumonia (PCP)
• Management of toxoplasmosis in immunocompromised patients
• Investigational antifolate in oncology (bladder, prostate cancers)
• Alternative to trimethoprim in sulfonamide-intolerant patients

• GMP Certified manufacturing facility in Aurangabad, Maharashtra, India
• Full pharmacopoeial compliance: IP / BP / USP standards
• Complete documentation: Certificate of Analysis (CoA), MSDS, Certificate of Origin
• Stringent in-process quality control at every manufacturing stage
• HPLC purity testing and spectroscopic identification (IR, NMR)
• Cold-chain and controlled-environment storage facilities available
• Exported to 40+ countries with full regulatory support